Skip to main content
Erschienen in: Endocrine 1/2018

22.02.2018 | Original Article

Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit

verfasst von: Joana Simões-Pereira, Joaquim Nunes, Ana Aguiar, Sandra Sousa, Cátia Rodrigues, Joaquim Sampaio Matias, Carlos Calhaz-Jorge

Erschienen in: Endocrine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Anti-Müllerian hormone (AMH) is a useful marker of ovarian reserve. Obesity/overweight are increasing and may affect the reproductive health. Previous studies regarding the effect of body mass index (BMI) on AMH levels are discordant. Our main goal was to evaluate the influence of BMI on AMH levels in women without polycystic ovarian syndrome.

Methods

Revision of medical records of 951 women who performed AMH determinations as part of their fertility workup, between 2011 and 2016.

Results

Median AMH concentration was 1.75 [interquartile range (IQR) 2] ng/mL (12.9 pmol/mL) and median age at AMH determination was 35 (IQR 6) years. These women evidenced a median BMI of 23 (IQR 5) kg/m2. Caucasian women were more represented [889(89.3%)]. Smoking habits (present/past) were present in 359(36.1%), and 147(14.8%) harboured a history of ovarian surgery. On univariable analysis AMH was not correlated with BMI (r = 0.048/p = 0.135); the only factors influencing AMH were age (p < 0.001), ethnicity (p = 0.004), and previous ovarian surgery (p < 0.001). On multivariable analysis, age was the only variable significantly associated with AMH, evidencing a reduction of 6.2% for each additional year (p < 0.0001). Furthermore, we verified a trend suggesting an AMH reduction of 22% (p = 0.08) in black patients comparing with the caucasian ones, when controlling for the other variables.

Conclusion

We report one of the largest series evaluating the influence of BMI on AMH levels and, consequently, on ovarian reserve. BMI does not seem to affect AMH levels. The reported concerns on infertility in overweight and obese women may be related to follicular development/oocyte maturation or endometrial disorders, rather than decreased ovarian reserve.
Literatur
1.
Zurück zum Zitat J.A. Visser, I. Schipper, J.S. Laven, A.P. Themmen, Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat. Rev. Endocrinol. 8, 331–341 (2012)CrossRefPubMed J.A. Visser, I. Schipper, J.S. Laven, A.P. Themmen, Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat. Rev. Endocrinol. 8, 331–341 (2012)CrossRefPubMed
2.
Zurück zum Zitat A. Dumont, G. Robin, S. Catteau-Jonard et al., Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review Dumont et al. Reprod. Biol. Endocrinol. 13, 137 (2015)CrossRefPubMedPubMedCentral A. Dumont, G. Robin, S. Catteau-Jonard et al., Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review Dumont et al. Reprod. Biol. Endocrinol. 13, 137 (2015)CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat E.W. Freeman, C.R. Gracia, M.D. Sammel et al., Association of anti-Müllerian hormone levels with obesity in late reproductive-age women. Fertil. Steril. 87, 101–106 (2007)CrossRefPubMed E.W. Freeman, C.R. Gracia, M.D. Sammel et al., Association of anti-Müllerian hormone levels with obesity in late reproductive-age women. Fertil. Steril. 87, 101–106 (2007)CrossRefPubMed
5.
Zurück zum Zitat E.W. Gregg, K.E. Shaw, Global health effects of overweight and obesity. N. Engl. J. Med. 12, 80–81 (2017)CrossRef E.W. Gregg, K.E. Shaw, Global health effects of overweight and obesity. N. Engl. J. Med. 12, 80–81 (2017)CrossRef
6.
Zurück zum Zitat M.W. Christensen, H.J. Ingerslev, B. Degn et al., Effect of female body mass index on oocyte quantity in fertility treatments (IVF): treatment cycle number is a possible effect modifier. a register-based cohort study. PLoS ONE 11, e0163393 (2016)CrossRefPubMedPubMedCentral M.W. Christensen, H.J. Ingerslev, B. Degn et al., Effect of female body mass index on oocyte quantity in fertility treatments (IVF): treatment cycle number is a possible effect modifier. a register-based cohort study. PLoS ONE 11, e0163393 (2016)CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat M. Nouri, E. Aghadavod, S. Khani et al., Association between BMI and gene expression of anti-Müllerian hormone and androgen receptor in human granulosa cells in women with and without polycystic ovary syndrome. Clin. Endocrinol. 85, 590–595 (2016)CrossRef M. Nouri, E. Aghadavod, S. Khani et al., Association between BMI and gene expression of anti-Müllerian hormone and androgen receptor in human granulosa cells in women with and without polycystic ovary syndrome. Clin. Endocrinol. 85, 590–595 (2016)CrossRef
8.
Zurück zum Zitat S. Sahmay, T. Usta, C.T. Erel et al., Is there any correlation between AMH and obesity in premenopausal women? Arch. Gynecol. Obst. 286, 661–665 (2012)CrossRef S. Sahmay, T. Usta, C.T. Erel et al., Is there any correlation between AMH and obesity in premenopausal women? Arch. Gynecol. Obst. 286, 661–665 (2012)CrossRef
9.
Zurück zum Zitat L.G. Nardo, D. Christodoulou, D. Gould et al., Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol. Endocrinol. 23, 486–493 (2007)CrossRefPubMed L.G. Nardo, D. Christodoulou, D. Gould et al., Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol. Endocrinol. 23, 486–493 (2007)CrossRefPubMed
10.
Zurück zum Zitat A.Z. Steiner, F.Z. Stanczyk, S. Patel et al., Anti-Müllerian hormone and obesity: insights in oral contraceptive users. Contraception 81, 245–248 (2010)CrossRefPubMed A.Z. Steiner, F.Z. Stanczyk, S. Patel et al., Anti-Müllerian hormone and obesity: insights in oral contraceptive users. Contraception 81, 245–248 (2010)CrossRefPubMed
11.
Zurück zum Zitat S. Halawaty, E. El Kattan, H. Azab et al., Effect of obesity on parameters of ovarian reserve in premenopausal women. J. Obstet. Gynaecol. Can. 32, 687–690 (2010)CrossRefPubMed S. Halawaty, E. El Kattan, H. Azab et al., Effect of obesity on parameters of ovarian reserve in premenopausal women. J. Obstet. Gynaecol. Can. 32, 687–690 (2010)CrossRefPubMed
12.
Zurück zum Zitat R.S. Legro, S.A. Arslanian, D.A. Ehrmann et al., Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 98, 4565–4592 (2013)CrossRefPubMedPubMedCentral R.S. Legro, S.A. Arslanian, D.A. Ehrmann et al., Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 98, 4565–4592 (2013)CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat A. Iwase, T. Nkamura, S. Osuka et al., Anti-Müllerian hormone as a marker of ovarian reserve: what have we learned, and what should we know? Reprod. Med. Biol. 15, 127 (2016)CrossRefPubMed A. Iwase, T. Nkamura, S. Osuka et al., Anti-Müllerian hormone as a marker of ovarian reserve: what have we learned, and what should we know? Reprod. Med. Biol. 15, 127 (2016)CrossRefPubMed
14.
Zurück zum Zitat M.M. Zain, R.J. Norman, Impact of obesity on female fertility and fertility treatment. Women’s Health 4, 183–194 (2008)CrossRefPubMed M.M. Zain, R.J. Norman, Impact of obesity on female fertility and fertility treatment. Women’s Health 4, 183–194 (2008)CrossRefPubMed
15.
Zurück zum Zitat M.A. Kominiarek, E.S. Jungheime, K.M. Hoeger et al., American Society for Metabolic and Bariatric surgery position statement on the impact of obesity and obesity treatment on fertility and fertility therapy endorsed by the American College of Obstetricians and Gynecologists and the Obesity Society. Surg. Obes. Relat. Dis. 13, 750–757 (2017)CrossRefPubMed M.A. Kominiarek, E.S. Jungheime, K.M. Hoeger et al., American Society for Metabolic and Bariatric surgery position statement on the impact of obesity and obesity treatment on fertility and fertility therapy endorsed by the American College of Obstetricians and Gynecologists and the Obesity Society. Surg. Obes. Relat. Dis. 13, 750–757 (2017)CrossRefPubMed
16.
Zurück zum Zitat B. Luke, M.B. Brown, J.E. Stern et al., Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. Hum. Reprod. 26, 245–252 (2011)CrossRefPubMed B. Luke, M.B. Brown, J.E. Stern et al., Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. Hum. Reprod. 26, 245–252 (2011)CrossRefPubMed
17.
Zurück zum Zitat R.J. H. Norman, L.R. Chura, R.L. Robker, Effects of obesity on assisted reproductive technology outcomes. Fertil. Steril. 89, 1611–1612 (2008)CrossRef R.J. H. Norman, L.R. Chura, R.L. Robker, Effects of obesity on assisted reproductive technology outcomes. Fertil. Steril. 89, 1611–1612 (2008)CrossRef
18.
Zurück zum Zitat P. X. Bhide, A. Gudi, A. Shah et al., Serum anti-Mullerian hormone levels across different ethnic groups: a cross-sectional study. BJOG 122, 1625–1629 (2015)CrossRef P. X. Bhide, A. Gudi, A. Shah et al., Serum anti-Mullerian hormone levels across different ethnic groups: a cross-sectional study. BJOG 122, 1625–1629 (2015)CrossRef
19.
Zurück zum Zitat M. Stracquadanio, L. Ciotta, M.A. Palumbo, Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women. Gynecol. Endocrinol. 23, 1–6 (2017) M. Stracquadanio, L. Ciotta, M.A. Palumbo, Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women. Gynecol. Endocrinol. 23, 1–6 (2017)
20.
Zurück zum Zitat N.F. Z. Goodman, R.H. Cobin, W. Futterweit et al., American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocr. Pract. 21, 1291–1300 (2017)CrossRef N.F. Z. Goodman, R.H. Cobin, W. Futterweit et al., American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocr. Pract. 21, 1291–1300 (2017)CrossRef
Metadaten
Titel
Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit
verfasst von
Joana Simões-Pereira
Joaquim Nunes
Ana Aguiar
Sandra Sousa
Cátia Rodrigues
Joaquim Sampaio Matias
Carlos Calhaz-Jorge
Publikationsdatum
22.02.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1555-y

Weitere Artikel der Ausgabe 1/2018

Endocrine 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.